US bank positive about Zealand's leaked fatty liver data

The new drug appears to provide significant improvement in liver fibrosis.
Photo: Thomas Traasdahl
Photo: Thomas Traasdahl
by marketwire

Zealand Pharma and partner Boehringer appear to be on the verge of publishing encouraging data from a study with the drug candidate Survodutide for the treatment of fatty liver disease, or MASH, according to US bank Jefferies.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading